India Pharma Outlook Team | Friday, 21 November 2025
Actimed Therapeutics today announced a licensing agreement with Mankind Pharma, giving the company exclusive rights to develop and commercialise Actimed’s products for the treatment and prevention of cachexia across India and several South Asian markets.
The deal strengthens Actimed’s presence in the region as efforts continue to bring new options to a condition with no globally approved therapies.
The agreement grants Mankind full territorial rights in India, Bangladesh, Bhutan, Nepal, Sri Lanka and Myanmar.
It covers Actimed’s current patents, know-how and any future related intellectual property within the defined field of use. Mankind will handle development, manufacturing and commercial activities under its own trademarks and will bear all related costs.
Also Read: Air Cargo's Role in Preserving Pharma Integrity in Transit
The licensed products include programmes based on Actimed’s technology, including S-pindolol benzoate (ACM-001.1), which is expected to enter phase 2b/3 clinical development for cancer cachexia. Subject to trial results and regulatory approval, Mankind will launch the product across the covered territories. Commercial terms were not disclosed.
Atish Majumdar, Senior President (sales & marketing) at Mankind Pharma and non-executive Director, Actimed, said, "Mankind has been a long-term supporter and shareholder of Actimed, and we are proud to deepen our partnership through this strategic licensing agreement."
Robin Bhattacherjee, Actimed CEO, said: "We are delighted to enter into this agreement with Mankind. Cachexia is a debilitating condition for which there are currently no globally approved therapies. By combining the Actimed cachexia product pipeline with Mankind’s strong development and commercial capabilities in its key markets, we are taking a major step forward in our aim to deliver meaningful treatment options to cachexia patients globally."
